PE20071152A1 - Compuestos derivados de azabiciclo[3.1.0]hex como moduladores de receptores de dopamina d3 - Google Patents
Compuestos derivados de azabiciclo[3.1.0]hex como moduladores de receptores de dopamina d3Info
- Publication number
- PE20071152A1 PE20071152A1 PE2007000392A PE2007000392A PE20071152A1 PE 20071152 A1 PE20071152 A1 PE 20071152A1 PE 2007000392 A PE2007000392 A PE 2007000392A PE 2007000392 A PE2007000392 A PE 2007000392A PE 20071152 A1 PE20071152 A1 PE 20071152A1
- Authority
- PE
- Peru
- Prior art keywords
- hex
- phenyl
- alkyl
- azabicycle
- dopamine
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 102000004073 Dopamine D3 Receptors Human genes 0.000 title abstract 2
- 108090000525 Dopamine D3 Receptors Proteins 0.000 title abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 201000007930 alcohol dependence Diseases 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE AZABICICLO[3.1.0]HEX DE FORMULA (I)' DONDE G ES FENILO, HETEROARILO MONOCICLICO DE 5 A 6 MIEMBROS O HETEROARILO BICICLICO DE 8 A 11 MIEMBROS; A ES UN COMPUESTO DE FORMULA (P1) O (P2), DONDE R4 ES H, HALOGENO, ALQUILO(C1-C4), CICLOALQUILO(C3-C7), ENTRE OTROS; R5 ES H, HIDROXI, HALOALQUILO(C1-C4), ALCOXI(C1-C4), ENTRE OTROS; p ES DE 0 A 5; R1 ES HALOGENO, CN, ALQUILO(C1-C4), ALCOXI(C1-C4), ENTRE OTROS; R2 ES H O ALQUILO(C1-C4); n ES DE 3 A 6; R7 ES H O ALQUILO(C1-C2). SON COMPUESTOS PREFERIDOS: 1-(3-{(1S,5R)-1-[4-(TRIFLUOROMETIL)FENIL]-3-AZABICICLO[3.1.0]HEX-3-IL}PROPIL)-2,4(1H,3H)-PIRIMIDINADIONA, 5-METIL-1-(3-{(1S,5R)-1-[4-(TRIFLUOROMETIL)FENIL]-3-AZABICICLO[3.1.0]HEX-3-IL}PROPIL)-2,4(1H,3H)-PIRIMIDINADIONA, 5-METIL-1-(4-{(1S,5R)-1-[4-(TRIFLUOROMETIL)FENIL]-3-AZABICICLO[3.1.0]HEX-3-IL}BUTIL)-2,4(1H,3H)-PIRIMIDINADIONA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LOS RECEPTORES DE DOPAMINA D3 SIENDO UTILES EN EL TRATAMIENTO DE ESQUIZOFRENIA, TRASTORNO PSICOTICO, ALCOHOLISMO, DEPRESION, ENFERMEDAD DE ALZHEIMER
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0607892A GB0607892D0 (en) | 2006-04-03 | 2006-04-03 | Novel compounds |
| GB0700363A GB0700363D0 (en) | 2007-01-09 | 2007-01-09 | Novel compounds |
| GB0703404A GB0703404D0 (en) | 2007-02-21 | 2007-02-21 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20071152A1 true PE20071152A1 (es) | 2007-12-16 |
Family
ID=38283980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007000392A PE20071152A1 (es) | 2006-04-03 | 2007-03-30 | Compuestos derivados de azabiciclo[3.1.0]hex como moduladores de receptores de dopamina d3 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7727988B2 (es) |
| EP (1) | EP2007750B1 (es) |
| JP (1) | JP5189074B2 (es) |
| KR (1) | KR20080109063A (es) |
| AR (1) | AR060237A1 (es) |
| AU (1) | AU2007233715A1 (es) |
| BR (1) | BRPI0709660A2 (es) |
| CA (1) | CA2648087A1 (es) |
| CR (1) | CR10346A (es) |
| EA (1) | EA200870404A1 (es) |
| ES (1) | ES2434337T3 (es) |
| IL (1) | IL194385A0 (es) |
| MA (1) | MA30355B1 (es) |
| MX (1) | MX2008012875A (es) |
| PE (1) | PE20071152A1 (es) |
| TW (1) | TW200815404A (es) |
| WO (1) | WO2007113232A1 (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1946714B (zh) * | 2004-02-23 | 2011-06-15 | 葛兰素集团有限公司 | 用作多巴胺d3受体调节剂的氮杂二环(3.1.0)己烷衍生物 |
| GB0507601D0 (en) * | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
| GB0507602D0 (en) * | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
| GB0512099D0 (en) * | 2005-06-14 | 2005-07-20 | Glaxo Group Ltd | Compounds |
| US7807698B2 (en) * | 2005-06-14 | 2010-10-05 | Glaxo Group Limited | Azabicyclo[3.1.0]hexane derivatives as modulators of the dopamine D3 receptor |
| GB0517187D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| GB0517191D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| GB0517193D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Novel use |
| GB0517175D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| ATE487715T1 (de) * | 2005-08-22 | 2010-11-15 | Glaxo Group Ltd | Triazolderivate als modulatoren von dopamin-d3- rezeptoren |
| WO2007113258A1 (en) * | 2006-04-03 | 2007-10-11 | Glaxo Group Limited | Azabicyclo [3. 1. o] hexane derivatives as modulators of dopamine d3 receptors |
| JP5189076B2 (ja) * | 2006-04-03 | 2013-04-24 | グラクソ グループ リミテッド | ドーパミンd3受容体のモジュレーターとしてのアザビシクロ[3.1.0]ヘキシル誘導体 |
| GB0719235D0 (en) | 2007-10-02 | 2007-11-14 | Glaxo Group Ltd | Novel compounds |
| RU2012102094A (ru) | 2009-06-26 | 2013-08-10 | Панацеа Биотек Лтд. | Новые азабициклогексаны |
| WO2011141474A1 (en) | 2010-05-12 | 2011-11-17 | Boehringer Ingelheim International Gmbh | Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| WO2014096965A2 (en) * | 2012-12-21 | 2014-06-26 | Rvx Therapeutics Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| JP6461121B2 (ja) | 2013-06-21 | 2019-01-30 | ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. | 新規の二環式ブロモドメイン阻害剤 |
| WO2015004534A2 (en) | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| CN105593224B (zh) | 2013-07-31 | 2021-05-25 | 恒元生物医药科技(苏州)有限公司 | 作为溴结构域抑制剂的新型喹唑啉酮类化合物 |
| EP3227280B1 (en) | 2014-12-01 | 2019-04-24 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
| US10710992B2 (en) | 2014-12-01 | 2020-07-14 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| US10292968B2 (en) | 2014-12-11 | 2019-05-21 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
| CN107406438B (zh) | 2014-12-17 | 2021-05-14 | 恒翼生物医药科技(上海)有限公司 | 溴结构域的抑制剂 |
| US11447484B2 (en) | 2018-01-26 | 2022-09-20 | Shionogi & Co., Ltd. | Cyclic compound having dopamine D3 receptor antagonistic effect |
| TWI702954B (zh) | 2018-03-01 | 2020-09-01 | 美商美國禮來大藥廠 | Cd73抑制劑 |
| LT3906927T (lt) * | 2020-05-04 | 2022-08-10 | Bioprojet Pharma | Dalinių dopamino d3 agonistų naudojimas centrinės nervų sistemos sutrikimams gydyti |
| WO2022121914A1 (zh) * | 2020-12-10 | 2022-06-16 | 上海翰森生物医药科技有限公司 | 氧代氮环类衍生物调节剂、其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6204284B1 (en) | 1991-12-20 | 2001-03-20 | American Cyanamid Company | Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies |
| DE4338396A1 (de) | 1993-11-10 | 1995-05-11 | Basf Ag | N-Substituierte Azabicycloalkan-Derivate, ihre Herstellung und Verwendung |
| DE4425143A1 (de) * | 1994-07-15 | 1996-01-18 | Basf Ag | Substituierte Pyrimidinverbindungen und deren Verwendung |
| DE10311065A1 (de) | 2003-03-13 | 2004-09-23 | Abbott Gmbh & Co. Kg | Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung |
| CN1946714B (zh) | 2004-02-23 | 2011-06-15 | 葛兰素集团有限公司 | 用作多巴胺d3受体调节剂的氮杂二环(3.1.0)己烷衍生物 |
| DE102004027359A1 (de) * | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyridin-2-onverbindungen und deren Verwendung |
| DE102004061593A1 (de) | 2004-12-21 | 2006-06-22 | Abbott Gmbh & Co. Kg | Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung |
| GB0507602D0 (en) | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
| GB0512099D0 (en) * | 2005-06-14 | 2005-07-20 | Glaxo Group Ltd | Compounds |
| GB0517191D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| JP5189076B2 (ja) | 2006-04-03 | 2013-04-24 | グラクソ グループ リミテッド | ドーパミンd3受容体のモジュレーターとしてのアザビシクロ[3.1.0]ヘキシル誘導体 |
| WO2007113258A1 (en) | 2006-04-03 | 2007-10-11 | Glaxo Group Limited | Azabicyclo [3. 1. o] hexane derivatives as modulators of dopamine d3 receptors |
-
2007
- 2007-03-30 KR KR1020087026817A patent/KR20080109063A/ko not_active Withdrawn
- 2007-03-30 JP JP2009503547A patent/JP5189074B2/ja not_active Expired - Fee Related
- 2007-03-30 MX MX2008012875A patent/MX2008012875A/es unknown
- 2007-03-30 WO PCT/EP2007/053074 patent/WO2007113232A1/en not_active Ceased
- 2007-03-30 PE PE2007000392A patent/PE20071152A1/es not_active Application Discontinuation
- 2007-03-30 ES ES07727546T patent/ES2434337T3/es active Active
- 2007-03-30 AR ARP070101352A patent/AR060237A1/es unknown
- 2007-03-30 BR BRPI0709660-7A patent/BRPI0709660A2/pt not_active Application Discontinuation
- 2007-03-30 AU AU2007233715A patent/AU2007233715A1/en not_active Abandoned
- 2007-03-30 US US11/693,756 patent/US7727988B2/en not_active Expired - Fee Related
- 2007-03-30 CA CA002648087A patent/CA2648087A1/en not_active Abandoned
- 2007-03-30 EA EA200870404A patent/EA200870404A1/ru unknown
- 2007-03-30 EP EP07727546.9A patent/EP2007750B1/en active Active
- 2007-04-02 TW TW096111521A patent/TW200815404A/zh unknown
-
2008
- 2008-09-25 IL IL194385A patent/IL194385A0/en unknown
- 2008-10-07 CR CR10346A patent/CR10346A/es not_active Application Discontinuation
- 2008-10-23 MA MA31328A patent/MA30355B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20080109063A (ko) | 2008-12-16 |
| AU2007233715A1 (en) | 2007-10-11 |
| MX2008012875A (es) | 2008-10-13 |
| WO2007113232A1 (en) | 2007-10-11 |
| CR10346A (es) | 2008-10-29 |
| MA30355B1 (fr) | 2009-04-01 |
| BRPI0709660A2 (pt) | 2011-07-19 |
| US20070249642A1 (en) | 2007-10-25 |
| AR060237A1 (es) | 2008-06-04 |
| JP5189074B2 (ja) | 2013-04-24 |
| TW200815404A (en) | 2008-04-01 |
| US7727988B2 (en) | 2010-06-01 |
| EP2007750B1 (en) | 2013-08-21 |
| EP2007750A1 (en) | 2008-12-31 |
| EA200870404A1 (ru) | 2009-04-28 |
| IL194385A0 (en) | 2009-08-03 |
| CA2648087A1 (en) | 2007-10-11 |
| ES2434337T3 (es) | 2013-12-16 |
| JP2009532424A (ja) | 2009-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20071152A1 (es) | Compuestos derivados de azabiciclo[3.1.0]hex como moduladores de receptores de dopamina d3 | |
| PE20121640A1 (es) | Derivados de pirazina como inhibidores de bace | |
| PE20121500A1 (es) | 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2 | |
| PE20120693A1 (es) | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) | |
| PE20120911A1 (es) | Derivados de prolina como inhibidores de catepsina | |
| PE20150230A1 (es) | Nuevos diazaespirocicloalcanos y azaespirocicloalcanos | |
| PE20060599A1 (es) | DERIVADOS PIRAZOLO-[3,4-d]-PIRIMIDINA COMO INHIBIDORES DE LA ACTIVIDAD DEL RECEPTOR CANNABINOIDE 1 | |
| PE20081783A1 (es) | Nuevas 2-aminooxazolinas como ligandos de taar1 | |
| PE20130155A1 (es) | Derivados de ariletinilo | |
| PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
| TNSN08372A1 (en) | Heterocyclic amides for use as pharmaceuticals | |
| PE20130279A1 (es) | Compuestos heteroarilo nitrogenados | |
| PE20091173A1 (es) | Derivados de heteroarilo como antagonistas de receptor de orexina | |
| PE20091724A1 (es) | Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7 | |
| PE20120101A1 (es) | Pirazoles fungicidas | |
| PE20090592A1 (es) | Nuevos derivados de piperazina-amida | |
| PE20110875A1 (es) | Derivados de isoindol como inhibidores de bace | |
| AR068115A1 (es) | Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida | |
| PE20140934A1 (es) | Derivados de pirazol | |
| PE20081345A1 (es) | Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico | |
| ATE486058T1 (de) | Prolinamidderivate als nk3-antagonisten | |
| PE20080525A1 (es) | Derivados de imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo como moduladores del receptor canabinoide 1 (cb1r) | |
| PE20091090A1 (es) | Derivados de piperidina como agonistas de receptores muscarinicos | |
| PE20110793A1 (es) | Derivados de (3-(4-cianofenil)-1h-pirazol-5 carboxamida como antagonistas del receptor de progesterona | |
| AR070797A1 (es) | Derivados de quinoxalinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |